Rehan Magnus Tablet
Naltrexone
50mg
Magnus Pharma Pvt. Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Available as:
Indications
Rehan Magnus Tablet is used for:
Opioid dependence, Alcohol dependence
Adult Dose
Opioid Dependence
Prevention of relapse after opioid detoxification; to be used only after patient has been opioid-free for 7-10 days and after negative naloxone challenge (no symptom withdrawal after naloxone administration)
PO: 25 mg initially, then observation for 1 hr, then 50 mg once daily starting on day 2; flexible dosing regimens can be employed to accommodate patient convenience or ensure compliance
IM: 380 mg in gluteal muscle every 4 weeks for maintenance of abstinence
Alcohol Dependence
Treatment in patients who have been able to abstain from alcohol in outpatient settings before treatment initiation
PO: 50 mg once daily for <12 weeks
IM: 380 mg in gluteal muscle every 4 weeks for maintenance of abstinence
Child Dose
Safety and efficacy not established
Renal Dose
Administration
May be taken with or without food.
Contra Indications
Patients concurrently dependent on opioids; acute hepatitis or hepatic failure; acute opioid withdrawal; patients on therapeutic opioid analgesics.
Precautions
Hepatic or renal impairment. Monitor LFTs regularly. Patients should be opioid-free for at least 7-10 days prior to initiating naltrexone therapy. Strictly warn patients against the use of opioids while on naltrexone. Monitor for inj-site reactions. Pregnancy, lactation. History of bleeding disorders (including thrombocytopenia).
Pregnancy-Lactation
Interactions
May reduce effects of opiate-containing preparations e.g. those used for cough and cold, diarrhoea and pain. Increased or decreased serum levels with drugs that alter hepatic metabolism. Potentially increased hepatotoxic effects with disulfiram. Increased risk of naltrexone-induced lethargy and somnolence with thioridazine. May increase insulin requirements.
Adverse Effects
Side effects of Naltrexone :
>10%
Injection site reaction (69%; includes bruising, induration, nodules, pain, pruritus, swelling, tenderness)
Nausea (33%),Headache (25%),Decreased appetite (14%),Insomnia (14%),Vomiting (14%),Diarrhea (13%),Dizziness (13%),Upper respiratory tract infection (URTI) (13%),Anxiety (12%),Arthralgia (12%),Increased creatine phosphokinase (11%),Pharyngitis (11%)
1-10%
Depression (8%),Muscle cramps (8%),Back pain (6%),Rash (6%),Dry mouth (5%),Somnolence (4%),Increased aspartate aminotransferase (AST) (2%)
<1%
Alopecia,Dyspnea,Edema,Hepatocellular injury,Increased systolic and diastolic blood pressures,Liver function abnormalities,Labored breathing,Nonspecific electrocardiographic (ECG) changes,Opiate withdrawal (mild to severe signs and symptoms, including drug craving, confusion, drowsiness, visual hallucinations, abdominal pain, vomiting, diarrhea),Palpitation,Phlebitis,Tachycardia
Mechanism of Action
Naltrexone acts as a competitive antagonist at opioid receptor sites. It blocks the action of opioids and precipitates withdrawal symptoms in opioid-dependent individuals.
Note
Rehan Magnus 50mg Tablet manufactured by Magnus Pharma Pvt. Ltd.. Its generic name is Naltrexone. Rehan Magnus is availble in Nepal.
Farmaco Nepal drug index information on Rehan Magnus Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.